Dashboard
Manage Tickers

BMY


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

looking-at-bristol-myers-squibbs-recent-unusual-options-activity
Looking At Bristol-Myers Squibb's Recent U...
07/02/2024 14:46:04

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
07/01/2024 17:35:22

what-the-options-market-tells-us-about-bristol-myers-squibb
What the Options Market Tells Us About Bri...
07/01/2024 16:31:06

novo-nordisk-buys-2seventys-hemophilia-a-program-divestiture-supports-exclusive-focus-on-abecma
Novo Nordisk Buys 2seventy's Hemophilia A ...
06/27/2024 17:17:39

2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editin...

what-the-options-market-tells-us-about-bristol-myers-squibb
What the Options Market Tells Us About Bri...
06/26/2024 15:33:00

fda-approves-bristol-myers-squibbs-combination-therapy-for-colorectal-cancer-patients-with-certain-type-of-gene-mutation
FDA Approves Bristol Myers Squibb's Combin...
06/24/2024 12:25:58

The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with K...

gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments
Gilead Sciences Faces Wall Street Speculat...
06/21/2024 15:42:22

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

the-european-medicines-agency-has-validated-the-extension-application-to-introduce-subcutaneous-administration-for-bristol-myers-squibbs-opdivo-nivolumab-and-a-new-strength-600-mgvial-across-multiple-previously-approved-adult-solid-tumor-indications
The European Medicines Agency Has Validate...
06/21/2024 11:03:36

Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of Opdivo to eval...

german-drug-developer-evotec-seeks-adviser-input-as-takeover-concerns-mount
German Drug Developer Evotec Seeks Adviser...
06/20/2024 17:46:42

Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
06/19/2024 17:35:26

this-is-what-whales-are-betting-on-bristol-myers-squibb
This Is What Whales Are Betting On Bristol...
06/18/2024 15:17:25

bristol-myers-squibb-says-fda-granted-accelerated-approval-to-augtyro-repotrectinib-for-patients-with-ntrk-positive-locally-advanced-or-metastatic-solid-tumors
Bristol Myers Squibb Says FDA Granted Acce...
06/13/2024 20:48:04

bristol-myers-receives-fda-accelerated-approval-for-repotrectinib
Bristol-Myers Receives FDA Accelerated App...
06/13/2024 17:14:39

- Bloomberg

Core News & Articles
Evotec Advances Neurodegeneration Research...
06/12/2024 07:45:36

bristol-myers-squibbs-options-frenzy-what-you-need-to-know
Bristol-Myers Squibb's Options Frenzy: Wha...
06/10/2024 17:16:04

smart-money-is-betting-big-in-bmy-options
Smart Money Is Betting Big In BMY Options
06/07/2024 20:46:14

fda-approves-gerons-first-commercial-drug-competes-with-bristol-myers-squibbs-blood-cancer-drug
FDA Approves Geron's First Commercial Drug...
06/07/2024 13:49:10

FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusi...

why-is-mid-cap-cancer-focused-replimune-stock-trading-higher-on-thursday
Why Is Mid-Cap Cancer-Focused Replimune St...
06/06/2024 16:16:20

Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rat...

Core News & Articles
I-Mab Enters Clinical Collaboration With B...
06/05/2024 11:02:19

The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody join...

bristol-myers-squibb-announces-phase-3-results-of-opdivoyervoy-combo-in-liver-cancer-patients
Bristol Myers Squibb Announces Phase 3 Res...
06/04/2024 15:35:18

Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)